Affymax, Inc. (NASDAQ:AFFY)
CAPS Rating:
The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.
The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.
Recs
Way too PRICY for its inherent value and for me at this point